Your browser doesn't support javascript.
loading
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa, Yasuyuki; Morita, Ryo; Mizugaki, Hidenori; Tateishi, Kazunari; Yokoo, Keiki; Sumi, Toshiyuki; Kikuchi, Hajime; Kitamura, Yasuo; Nakamura, Atsushi; Kobayashi, Maki; Aso, Mari; Kimura, Nozomu; Yoshiike, Fumiaki; Megumi, Furuta; Tanaka, Hisashi; Sekikawa, Motoki; Hachiya, Tsutomu; Nakamura, Keiichi; Hommura, Fumihiro; Sukoh, Noriaki; Ito, Kenichiro; Kikuchi, Takashi; Agatsuma, Toshihiko; Yokouchi, Hiroshi.
Afiliación
  • Ikezawa Y; Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan.
  • Morita R; Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Mizugaki H; Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan.
  • Tateishi K; Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
  • Yokoo K; Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Sumi T; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
  • Kikuchi H; Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan.
  • Kitamura Y; Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan.
  • Nakamura A; Department of Respiratory Medicine, Obihiro-Kousei General Hospital, Obihiro, Japan.
  • Kobayashi M; Department of Respiratory Medicine, Kushiro City General Hospital, Kushiro, Japan.
  • Aso M; Department of Pulmonary Medicine, Sendai Kousei General Hospital, Sendai, Japan.
  • Kimura N; Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
  • Yoshiike F; Department of Respiratory Medicine, Yamagata Prefectural Central Hospital, Yamagata, Japan.
  • Megumi F; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Tanaka H; Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
  • Sekikawa M; Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Hachiya T; Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan.
  • Nakamura K; Department of Respiratory Medicine, Steel Memorial Muroran Hospital, Muroran, Japan.
  • Hommura F; Department of Respiratory Medicine, Japanese Red Cross Suwa Hospital, Suwa, Japan.
  • Sukoh N; Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
  • Ito K; Department of Respiratory Medicine, Sapporo City General Hospital, Sapporo, Japan.
  • Kikuchi T; Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
  • Agatsuma T; Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan.
  • Yokouchi H; Department of Respiratory Medicine, Iwate Prefecture Isawa Hospital, Oshu, Japan.
Cancer Med ; 13(14): e70036, 2024 Jul.
Article en En | MEDLINE | ID: mdl-39030894
ABSTRACT

BACKGROUND:

Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue in clinical practice. We previously conducted a retrospective multicenter observational study of patients with NSCLC and high PD-L1 expression who received MONO or COMB as a first-line treatment. Here, we report updated data and evaluate the long-term outcomes.

METHODS:

We performed a retrospective multicenter study of 298 patients with NSCLC and high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records and assessed the clinical efficacy and toxicity using a prolonged data cutoff.

RESULTS:

In total, 164 (median age 74 years) and 134 (median age 68 years) patients received MONO and COMB, respectively; patients who received COMB were younger and had better performance statuses (0-1). At the prolonged data cutoff, the median follow-up was 20.2 (range 0.1-41.4) months. The median progression-free survivals were 7.5 and 13.1 months, and overall survivals (OSs) were 17.2 and 33.7 months for MONO and COMB, respectively. Treatment discontinuation rates were 21.9% and 20.1% for the MONO and COMB, respectively. With prolonged follow-up, although COMB demonstrated an OS benefit and higher objective response rate than MONO, in the propensity score matching analysis COMB didn't demonstrate a significant benefit compared to the MONO.

CONCLUSIONS:

COMB may be effective as a first-line treatment for NSCLC with high PD-L1 expression in a selected subset of patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias Pulmonares Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias Pulmonares Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos